GHRP-2 Research for GH Deficiency Diagnosis
An evidence-based overview of research examining GHRP-2 in the context of gh deficiency diagnosis. This page synthesizes findings from peer-reviewed literature.
Research Summary
GHRP-2 (as Pralmorelin) is approved in Japan for diagnosing growth hormone deficiency. The compound produces consistent, potent GH release that allows assessment of pituitary reserve. Phase 2/3 trials demonstrated comparable sensitivity and specificity to the insulin tolerance test with a superior safety profile.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. GHRP-2 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.